Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Restructuring Costs (2018 - 2021)

Historic Restructuring Costs for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Q3 2021 value amounting to -$73000.0.

  • Ironwood Pharmaceuticals' Restructuring Costs fell 10592.53% to -$73000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $14.1 million, marking a year-over-year increase of 126595.74%. This contributed to the annual value of $15.4 million for FY2020, which is 32541.44% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Restructuring Costs stood at -$73000.0 for Q3 2021, which was down 10592.53% from -$282000.0 recorded in Q2 2021.
  • In the past 5 years, Ironwood Pharmaceuticals' Restructuring Costs registered a high of $14.2 million during Q4 2020, and its lowest value of -$282000.0 during Q2 2021.
  • In the last 4 years, Ironwood Pharmaceuticals' Restructuring Costs had a median value of $705000.0 in 2018 and averaged $2.6 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Restructuring Costs surged by 4437500.0% in 2020 and then crashed by 10592.53% in 2021.
  • Ironwood Pharmaceuticals' Restructuring Costs (Quarter) stood at $705000.0 in 2018, then crashed by 104.54% to -$32000.0 in 2019, then soared by 44375.0% to $14.2 million in 2020, then plummeted by 100.52% to -$73000.0 in 2021.
  • Its Restructuring Costs was -$73000.0 in Q3 2021, compared to -$282000.0 in Q2 2021 and $311000.0 in Q1 2021.